Figures computed from official regulatory filings — .
Analysttarget 38.25 USD (+147%) · consensus 5/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 19.06% · institutions 73.76% · short 1.5% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Eloxx Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
208 buys16 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Domicilium Real Estate Fund III LP | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Domicilium Real Estate Fund III LP | Other | n/a (No price was disclosed in the filing) | SEC |
| Domicilium Real Estate Fund III LP | Other | n/a (No price was disclosed in the filing) | SEC |
| Walts Alan Edmund | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rubin Steven Dtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Kjellson Nina S | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Webster Stephen W | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Domicilium Real Estate Fund III LP | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Domicilium Real Estate Fund III LP | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Coastlands Capital LPtrack record | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Coastlands Capital LPtrack record | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | Award | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Walts Alan Edmund | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | Exercise | $19.7 | SEC |
| Aggarwal Sumit | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Aggarwal Sumit | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Aggarwal Sumit | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Rubin Steven Dtrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Walts Alan Edmund | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Aggarwal Sumit | Exercise | $39.1K | Unusual size | SEC |
| Aggarwal Sumit | OtherD (derivative) | n/a (No price was disclosed in the filing) | SEC |